Primary and secondary drug resistance to imatinib and sunitinib in patients with gastrointestinal stromal tumors (GISTs) has led to a pressing need for new therapeutic strategies such as drug combinations. Mos...
Authors:
Maria Abbondanza Pantaleo, Giordano Nicoletti, Cristina Nanni, Chiara Gnocchi, Lorena Landuzzi, Carmelo Quarta, Stefano Boschi, Margherita Nannini, Monica Di Battista, Paolo Castellucci, Stefano Fanti, Pier Luigi Lollini, Elena Bellan, Mauro Castelli, Domenico Rubello and Guido Biasco
Citation:
Journal of Experimental & Clinical Cancer Research
2010
29:173
Content type: Research
Published on: 30 December 2010